GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,359.20
+4.20 (+0.31%)
At close: 4:35PM GMT
Stock chart is not supported by your current browser
Previous close1,355.00
Open1,365.60
Bid1,350.00 x 175400
Ask1,372.00 x 417900
Day's range1,357.80 - 1,377.78
52-week range1,270.00 - 1,724.50
Volume11,051,536
Avg. volume10,567,207
Market cap65.997B
Beta1.15
PE ratio (TTM)28.74
EPS (TTM)47.30
Earnings date7 Feb 2018
Forward dividend & yield1.01 (5.14%)
Ex-dividend date2017-08-10
1y target est1,554.93
  • Reuters2 hours ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline (GSK.L) is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region. Five years ago, forecasters predicted annual African drug sales would reach $45 billion by 2020.

  • Reuters - UK Focus2 hours ago

    Drugmaker GSK cuts back in Africa to hone emerging markets model

    GlaxoSmithKline (Other OTC: GLAXF - news) is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region. Today, the same experts at research company IQVIA, previously known as IMS Health (NYSE: IMS - news) , suggest it is more likely to be around $25 billion.

  • MarketWatch6 hours ago

    NeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell

    Shares of NeuroMetrix Inc. rocketed 78% toward a 7-month high in active premarket trade Wednesday, after chronic pain treatments company announced a collaboration with GlaxoSmithLine PLC involving NeuroMetrix's ...

  • Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa
    Bloomberg6 hours ago

    Glaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa

    GlaxoSmithKline Plc is cutting jobs in Africa and restructuring in more than two dozen countries across the continent, reversing earlier expansion efforts as new Chief Executive Emma Walmsley tries to ...

  • Globe Newswire6 hours ago

    NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology

    NeuroMetrix, Inc. (Nasdaq:NURO) announced today a collaboration with GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare companies, involving Quell® Wearable Pain Relief Technology™. GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. NeuroMetrix retains exclusive ownership of Quell technology in the U.S. market.

  • Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
    Zacks2 days ago

    Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

    Glaxo's (GSK) influenza vaccine ??? Fluarix Quadrivalent receives FDA approval for label expansion.

  • 2 stocks I’d own during a 2018 market correction
    Fool.co.uk2 days ago

    2 stocks I’d own during a 2018 market correction

    Nervous investors may find these high-income, non-cyclical businesses great places to park their cash in 2018.

  • Reuters - UK Focus3 days ago

    Google venture arm backs UK universal flu vaccine company

    A private British company developing a vaccine that would be the first in the world to fight all types of flu has raised 20 million pounds ($27 million) from investors including GV, the venture capital arm of Google parent Alphabet Inc (Xetra: ABEA.DE - news) . Vaccitech, a spin-out founded by scientists at Oxford University's Jenner Institute, said on Monday the cash would help fund its vaccine through a two-year clinical trial involving more than 2,000 patients and expand other projects.

  • Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
    Zacks5 days ago

    Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

    Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

  • Reuters8 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Reuters8 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco. Despite her consumer products background, Walmsley repeatedly said that the company's pharmaceuticals business and pharma research and development is GSK's top priority.

  • Reuters - UK Focus8 days ago

    GSK CEO says looking at Pfizer consumer business, but not a priority

    GlaxoSmithKline (Other OTC: GLAXF - news) 's new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc (NYSE: PFE - news) 's consumer products business, but would not overpay for the asset. Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire. "At this stage it would be weird if we didn't look at it," GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco.

  • Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In
    Bloomberg8 days ago

    Glaxo Shifts Gears to Fire Up Growth With Rival Astra Closing In

    CEO Walmsley has reshuffled 40 percent of top managers to spark innovation

  • The Wall Street Journal8 days ago

    Rivals Help Fund Regeneron’s Gene-Sequencing Effort

    Some of the world’s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.

  • Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth
    Bloomberg9 days ago

    Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth

    GlaxoSmithKline Plc’s new chief executive officer, Emma Walmsley, has revamped the top ranks of the U.K.’s largest drugmaker, replacing about 50 of the top 125 managers since taking over last year.

  • 1 Reason Dynavax Technologies Corporation Stock Soared in 2017
    Motley Fool9 days ago

    1 Reason Dynavax Technologies Corporation Stock Soared in 2017

    Thanks to the FDA approval of its hepatitis B vaccine, Dynavax's shares crushed the broader market in 2017.

  • Why GlaxoSmithKline plc shares could be the buy of the decade
    Fool.co.uk11 days ago

    Why GlaxoSmithKline plc shares could be the buy of the decade

    After a challenging few years, the fortunes of GlaxoSmithKline plc (LON:GSK) could be set for a dramatic improvement.

  • Reuters - UK Focus12 days ago

    BUZZ-CRISPR Therapeutics soars to fresh record after upsized stock offering

    ** CRISPR Therapeutics shares reverse premarket losses and soar to new record high after co's upsized equity raise ** Stock jumps as much as 19.2 pct to $28.499 on Fri; has traded over 3 mln shares, its ...

  • Globe Newswire13 days ago

    Paul Stead Joins Adaptimmune as Vice President of Business Development

    PHILADELPHIA, Pa. and OXFORD, England, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Paul Stead, B. Pharm, PhD, MBA, MR PharmS has joined the Company as Vice President of Business Development.

  • Should I swap GlaxoSmithKline plc for this turnaround stock?
    Fool.co.uk13 days ago

    Should I swap GlaxoSmithKline plc for this turnaround stock?

    Could this company offer higher returns than GlaxoSmithKline plc (LON:GSK)?

  • Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?
    Investor's Business Daily14 days ago

    Spark, Glaxo Gene Therapies Near $1 Million — Still A Bargain?

    Spark and GlaxoSmithKline are pricing the world's first approved gene therapies at prices approaching $1 million.

  • U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy
    Bloomberg15 days ago

    U.K. Clears Glaxo's $700,000 ‘Bubble Boy Disease’ Gene Therapy

    The U.K.’s thrifty health authority has cleared its most expensive medicine ever -- a $700,000 GlaxoSmithKline Plc treatment for an illness known as “bubble-boy disease.” But the overall cost to the country’s ...

  • 3 Top Dividend Stocks With Yields Over 4%
    Motley Fool17 days ago

    3 Top Dividend Stocks With Yields Over 4%

    High-yield stocks have gotten harder to find in the current bull market, but these three should please even the pickiest income investors.

  • Barrons.com19 days ago

    [$$] Glaxo: Expect a Speedy Recovery

    Advair, the world’s top-selling respiratory drug, will probably face generic competition in the U.S. beginning in 2018. It’s the biggest moneymaker for United Kingdom-based GlaxoSmithKline , whose earnings estimates have been sliding, and whose shares have tumbled since the summer. To see why, look back to Pfizer (PFE) seven years ago, on the eve of Lipitor’s patent expiration.

  • Market Realist22 days ago

    Measuring Sanofi’s Valuation This December

    For 3Q17, Sanofi reported revenues of 9.05 billion euros—a 4.7% YoY (year-over-year) rise in operating revenues, compared with 9.03 billion in 3Q16.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes